Clinical Trials Using Antibody-drug Conjugate PF-06647020

Clinical trials are research studies that involve people. The clinical trials on this list are studying Antibody-drug Conjugate PF-06647020. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Gedatolisib and Antibody-drug Conjugate PF-06647020 in Treating Patients with Metastatic Triple Negative Breast Cancer

    This phase I trial studies the side effects of gedatolisib and antibody-drug conjugate PF-06647020 and how well they work in treating patients with triple negative breast cancer that has spread to other places in the body. Gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as antibody-drug conjugate PF-06647020, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gedatolisib and antibody-drug conjugate PF-06647020 may work better than gedatolisib alone in treating patients with triple negative breast cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana